testosterone cypionate reviews

The drug is usually ineffective in absence seizures (petit mal) and myoclonic seizures. The drug should be used only on condition that the regular medical supervision.
During the drug at different rates observed transient or persistent decrease in the number of platelets or leukocytes. However, in most cases, these effects are transient and usually are not harbingers of the beginning of aplastic anemia or agranulocytosis. Before starting treatment, testosterone cypionate reviews and periodically during treatment should be carried out clinical blood tests, including counting the number of platelets and possibly reticulocytes as well as to determine the concentration of iron in the blood serum.
It is necessary to inform patients about the early signs of toxicity inherent probable hematological disorders as well as the symptoms of the skin and liver.
The patient was informed of the need to consult a doctor immediately in case of occurrence of such adverse reactions, such as fever, sore throat, rash, ulcers in the mouth, wanton appearance of bruises, hemorrhages in the form of petechiae or purpura.
When using Tegretol rarely observed severe dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell’s syndrome). With the development of heavy (in some cases life-threatening patient) skin reactions, the patient should be admitted to the hospital. In most cases, Stevens-Johnson and Lyell’s syndrome syndrome developed in the first months of drug therapy.
According to a retrospective analysis of the drug in patients with Chinese nationality there is a correlation between the frequency of severe dermatological reactions and the presence in the genome of the patient allele HLA-B * 1502 gene of human leukocyte antigentestosterone cypionate reviews.
in the application of carbamazepine in patients in the countries of Asia (Thailand, Malaysia, the Philippines), where there is a preferential distribution was found an increase in the incidence (from “very rare” graduation to “rarely”) severe dermatological reactions, including Stevens-Johnson syndrome, Lyell syndrome. Frequency Distribution of  *  is as follows: in the Philippines, Thailand, Hong Kong and Malaysia -more than 15%, in Taiwan – 10%, in North China – 4% in South Asia, including India – 2-4% in Japan, Korea and – less than 1%. The prevalence of this allele in individuals Caucasoid, Negroid and Americanoid (Latinos and Indians) races is negligible.
In the appointment of carbamazepine possible carriers (for example, persons of Chinese nationality) recommended genotyping on the allele. Prescribers should be carriers of this allele only if the benefits of therapy outweighs the potential risk. The person Caucasoid, Negroid and Americanoid races conducting genotyping testosterone cypionate reviewsbefore the appointment of Tegretol is not necessary.
Patients already receiving therapy Tegretol is not recommended to perform genotyping on the allele as severe skin reactions in the majority of cases were recorded in the first months of the drug (regardless of the presence of HLA-B * 1502 allele).
However, the results of genotyping testosterone cypionate reviewsshould not affect the degree of control over the condition of the patient and watchful physician regarding serious skin reactions development of Stevens-Johnson syndrome and toxic epidermal necrolysis possible in patients negative . Also, in many cases, persons of Chinese nationality positive  in the application of Tegretol is not mentioned of Stevens-Johnson syndrome and toxic epidermal necrolysis.
The influence of other factors such as the dose of anticonvulsant drugs, compliance of patients, simultaneous treatment with other drugs, comorbidities or the level of control of dermatological reactions, the incidence of severe skin reactions (and mortality in patients with the syndrome of Stevens-Johnson syndrome and toxic epidermal necrolysis) have not been established.